Table 2 Mortalities according to RAAS inhibitor use.

From: The use of renin angiotensin aldosterone system inhibitors may be associated with decreased mortality after cancer surgery

 

No RAAS inhibitor

RAAS inhibitor

Unadjusted HR (CI)

p-value

Adjusted HR (CI)

p-value

Entire population

n = 8374

n = 11,391

    

Mortality

5-year mortality, no (%)

984 (11.8)

1006 (8.8)

0.78 (0.72–0.85)

 < 0.001

0.75 (0.67–0.84)

 < 0.001

3-year mortality, no (%)

788 (9.4)

805 (7.1)

0.77 (0.70–0.85)

 < 0.001

0.74 (0.66–0.84)

 < 0.001

1-year mortality, no (%)

334 (4.0)

323 (2.8)

0.71 (0.61–0.83)

 < 0.001

0.72 (0.60–0.87)

 < 0.001

Recurrence

5-year recurrence, no (%)

479 (5.7)

478 (4.2)

0.77 (0.68–0.88)

 < 0.001

0.83 (0.70–0.97)

0.02

3-year recurrence, no (%)

332 (4.0)

316 (2.8)

0.73 (0.62–0.85)

 < 0.001

0.78 (0.65–0.95)

0.01

1-year recurrence, no (%)

82 (1.0)

68 (0.6)

0.61 (0.45–0.85)

0.003

0.83 (0.57–1.21)

0.33

Cancer-specific mortality

5-year mortality, no (%)

469 (5.6)

447 (3.9)

0.72 (0.64–0.82)

 < 0.001

0.69 (0.58–0.81)

 < 0.001

3-year mortality, no (%)

408 (4.9)

393 (3.5)

0.73 (0.63–0.83)

 < 0.001

0.69 (0.58–0.82)

 < 0.001

1-year mortality, no (%)

192 (2.3)

182 (1.6)

0.70 (0.57–0.86)

 < 0.001

0.70 (0.55–0.90)

 < 0.001

Propensity-score matched population

n = 5022

n = 5022

    

Mortality

5-year mortality, no (%)

574 (11.4)

373 (7.4)

  

0.73 (0.64–0.83)

 < 0.001

3-year mortality, no (%)

458 (9.1)

308 (6.1)

  

0.73 (0.63–0.84)

 < 0.001

1-year mortality, no (%)

189 (3.8)

126 (2.5)

  

0.68 (0.54–0.85)

0.001

Recurrence

5-year recurrence, no (%)

267 (5.3)

187 (3.7)

  

0.82 (0.68–0.99)

0.04

3-year recurrence, no (%)

182 (3.6)

130 (2.6)

  

0.79 (0.63–1.00)

0.045

1-year recurrence, no (%)

33 (0.7)

33 (0.7)

  

1.03 (0.63–1.67)

0.91

Cancer-specific mortality

5-year mortality, no (%)

268 (5.3)

167 (3.3)

  

0.69 (0.56–0.83)

 < 0.001

3-year mortality, no (%)

230 (4.6)

150 (3.0)

  

0.70 (0.57–0.86)

 < 0.001

1-year mortality, no (%)

100 (2.0)

74 (1.5)

  

0.75 (0.56–1.02)

0.06

  1. Multivariable adjustment included age, sex, diabetes, coronary artery disease, heart failure, stroke, deep vein thrombosis, chronic kidney disease, chronic lung disease, anemia, preoperative chemotherapy, preoperative radiotherapy, preoperative metastasis, the number of intraoperatively transfused red bold cell units, continuous infusion of inotropes, duration of operation and preoperative use of RAAS inhibitors.
  2. RAAS renin–angiotensin–aldosterone system, HR hazard ratio, CI confidence interval.
Back to article page